Impact Factor 3.845 | CiteScore 3.92
More on impact ›

Review ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Pharmacol. | doi: 10.3389/fphar.2019.01276

Immune and smooth muscle cells interactions in atherosclerosis: how to target a breaking bad dialogue?

 Damien RAMEL1,  Stéphanie Gayral1, Marie-Kerguelen Sarthou1,  Nathalie Augé1, Anne Nègre-Salvayre1 and  Muriel Laffargue1*
  • 1INSERM U1048 Institut des Maladies Métaboliques et Cardiovasculaires, France

Inflammation is a well-known pathophysiological actor of atherosclerosis but its therapeutic targeting has long been ignored. However, recent advances in the understanding of the immune mechanisms implicated in atherosclerosis have unveiled several therapeutic targets currently undergoing clinical trials. These studies have also shed light on a dialogue between the immune compartment and vascular smooth muscle cells (VSMCs) that plays a critical role in atherosclerotic disease initiation, progression and stabilization. Our review focuses on the link between cellular and soluble immune effectors and VSMC behavior at different phases of the pathology. Furthermore, we discuss the potential targeting of these interactions to efficiently prevent cardiovascular diseases.

Keywords: Inflammation, Atherosclerosis, smooth muscle cells, Therapeutic target, Cardiovascular Diseases

Received: 19 Jul 2019; Accepted: 07 Oct 2019.

Copyright: © 2019 RAMEL, Gayral, Sarthou, Augé, Nègre-Salvayre and Laffargue. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dr. Muriel Laffargue, INSERM U1048 Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, 31432, France, muriel.laffargue@inserm.fr